List of Xelstrym drug patents
Xelstrym is owned by Noven Pharms Inc.
Xelstrym contains Dextroamphetamine.
Xelstrym has a total of 6 drug patents out of which 0 drug patents have expired.
Xelstrym was authorised for market use on 22 March, 2022.
Xelstrym is available in system;transdermal dosage forms.
Xelstrym can be used as a method of treating attention deficit hyperactivity disorder by administering a transdermal composition containing amphetamine.
The generics of Xelstrym are possible to be released after 06 January, 2042.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9034370 | NOVEN PHARMS INC | Device for transdermal administration of drugs including acrylic polymers |
Oct, 2025
(2 years from now) | |
| US8591941 | NOVEN PHARMS INC | Transdermal drug delivery device including an occlusive backing |
Oct, 2025
(2 years from now) | |
| US8632802 | NOVEN PHARMS INC | Device for transdermal administration of drugs including acrylic polymers |
Oct, 2025
(2 years from now) | |
| US9456993 | NOVEN PHARMS INC | Compositions and methods for transdermal delivery of amphetamine |
Oct, 2033
(10 years from now) | |
| US9474722 | NOVEN PHARMS INC | Compositions and methods for transdermal delivery of amphetamine |
Oct, 2033
(10 years from now) | |
| US11559501 | NOVEN PHARMS INC | Transdermal amphetamine compositions with low levels of carbamate |
Jan, 2042
(18 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Product (NP) | Mar 22, 2025 |
Drugs and Companies using DEXTROAMPHETAMINE ingredient
Market Authorisation Date: 22 March, 2022
Treatment: A method of treating attention deficit hyperactivity disorder by administering a transdermal composition containing amphetamine
Dosage: SYSTEM;TRANSDERMAL
XELSTRYM family patents
26
United States
3
Argentina
3
Canada
3
Spain
3
Taiwan, Province of China
3
European Union
2
Mexico
1
Hong Kong
1
Japan
1
Australia
1
Peru
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic